Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease

[1]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[2]  F. Lampe,et al.  The natural history of prevalent ischaemic heart disease in middle-aged men. , 2000, European heart journal.

[3]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[4]  R. Dobson,et al.  Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. , 2005, The Canadian journal of cardiology.

[5]  K Cooper,et al.  Choice of modelling technique for evaluating health care interventions , 2007, J. Oper. Res. Soc..

[6]  K Cooper,et al.  Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction , 2005, Emergency Medicine Journal.

[7]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[8]  Ruth Davies,et al.  The Development of a Simulation Model of the Treatment of Coronary Heart Disease , 2002, Health care management science.

[9]  R Davies,et al.  Modelling patient flows and resource provision in health systems , 1994 .

[10]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[11]  Northgate.  Hospital Episode Statistics , 2006 .

[12]  A F Mackintosh,et al.  Use of cumulative mortality data in patients with acute myocardial infarction for early detection of variation in clinical practice: observational study , 2001, BMJ : British Medical Journal.

[13]  Bhash Naidoo,et al.  The Development of a Simulation Model of Primary Prevention Strategies for Coronary Heart Disease , 2002, Health care management science.

[14]  David L. Wilson,et al.  The analysis of survival (mortality) data: Fitting Gompertz, Weibull, and logistic functions , 1994, Mechanisms of Ageing and Development.

[15]  D. Mant,et al.  Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). The SHIP Collaborative Group. , 1999, BMJ.

[16]  S. Nuttall,et al.  beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. , 2000, BMJ.

[17]  Tso.  Health Survey for England: Cardiovascular Disease '98 , 2000 .

[18]  D. Mant,et al.  General practice Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina : final results of the Southampton heart integrated care project ( SHIP ) , 1999 .

[19]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[20]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[21]  M. Wright,et al.  Incidence of coronary heart disease in a health authority in London: review of a community register , 2003, BMJ : British Medical Journal.

[22]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[23]  J. Birkhead.  Where are we today? Early results from MINAP, the national audit of myocardial infarction project , 2003, Heart.

[24]  K Cooper,et al.  A review of health care models for coronary heart disease interventions , 2006, Health care management science.

[25]  M. Fitzpatrick.  Getting to the heart of it. , 2001, Nursing management.

[26]  Collinson.  Clinical outcomes, risk stratification practice patterns and health economics of acute coronary syndromes without ST elevation : prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK). , 1999 .

[27]  G. Goldberg,et al.  Health Survey for England: Cardiovascular Disease ’98 , 2000 .

[28]  J. Critchley,et al.  prevention and secondary prevention comparing contributions from primary deaths in England and Wales, 1981-2000: Modelling the decline in coronary heart disease , 2005 .

[29]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[30]  J. Critchley,et al.  Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention , 2005, BMJ : British Medical Journal.